Postoperative Pain Management Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Postoperative Pain Management Market is Segmented by Drug Class (Opioids, Non-steroidal anti-inflammatory drugs (NSAIDs), Cyclooxygenase-2-selective inhibitors (COX-2) inhibitors, and Other Drug classes), by Route of Administration (Injectable, Oral, Topical and Other Routes), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Other Distribution Channels) and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa and South America). The report offers the value (USD million) for the above segments.

Market Snapshot

Post Operative Pain Management Market Size
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 4.8 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The postoperative pain management market is expected to register a CAGR of 4.8% over the forecast period, 2022-2027.

The COVID-19 pandemic has significantly impacted the postoperative pain management market. For instance, as per a December 2020 published article titled "COVID-19 and its impact on pain management practices", irrespective of the place of pain practice, 95.2% of physicians reported that their pain practice was affected. As per the same study, physicians reported that fewer patients visited the pain clinic, and fewer interventions were performed. However, with the introduction of vaccines and the uplifting of lockdown restrictions, the number of surgical procedures started to increase gradually, positively impacting the market growth. For instance, as per a January 2021 published study titled, "Postoperative outcomes in surgical COVID-19 patients: a multicenter cohort study", postoperative 30-day mortality in COVID-19 patients undergoing surgery was high (15.9%). As per the same study, although few surgeries were performed on COVID-19 patients, the pandemic impact on surgical activity volume was significant. Such studies indicate the increasing demand for postoperative pain management medications during the COVID-19 pandemic.

Furthermore, the factors fueling the market's growth are the growing number of surgical procedures, rising number of emergency hospital visits, increasing demand for non-opioid-based analgesics, and increasing focus on palliative care.

A growing number of surgical procedures drives the demand for postoperative pain management medications. For instance, as per the research study published in June 2021, titled "German Heart Surgery Report 2020: The Annual Updated Registry of the German Society for Thoracic and Cardiovascular Surgery", a total of 92,809 operations were classified as heart surgery procedures in the classical sense, of which 29,444 were isolated coronary artery bypass grafting procedures, 35,469 were isolated heart valve procedures, and the number of isolated heart transplantations increased by 2% to 340. In addition, according to the Organization for Economic Co-operation and Development (OECD), the estimated number of laparoscopic cholecystectomy procedures performed in Italy in 2020 was 61,313 and 118,485 in Turkey. With such an increase in the number of surgeries performed across several countries, the market for postoperative pain management drugs is expected to exhibit substantial growth as these medications play a crucial role in managing the pain caused by surgical procedures.

Likewise, a study titled "Postoperative Pain Management in Enhanced Recovery Pathways" published in PubMed Central in January 2022 stated that, according to United States Institute of Medicine research, postoperative pain is a common but often undertreated disease, with 80 percent of surgery patients experiencing postoperative pain and less than half of these patients reporting appropriate pain control. Furthermore, the study states that, according to a nationwide survey, 39 percent of postoperative patients feel severe to terrible pain. Such unmet needs greatly highlight the need for postoperative pain management drugs to optimize palliative care among the patient population, thereby providing lucrative opportunities to prominent players within the market.

However, concerns about the overuse of opioids are a major factor restraining the market's growth.

Scope of the Report

Per the report's scope, postoperative pain is defined as a complex response to tissue trauma post-surgical procedures. It comprises both surgery-related pain and pain linked with central nervous system hypersensitivity. The purpose of postoperative pain management medications is to minimize adverse effects while reducing or eliminating pain and discomfort. The Postoperative Pain Management Market is Segmented by Drug Class (Opioids, Non-steroidal anti-inflammatory drugs (NSAIDs), Cyclooxygenase-2-selective inhibitors (COX-2) inhibitors, and Other Drug classes), by Route of Administration (Injectable, Oral, Topical and Other Routes), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Other Distribution Channels) and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments. The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (in USD million) for the above segments.

By Drug Class
Opioids
Non-steroidal anti-inflammatory drugs (NSAIDS)
Cyclooxygenase-2-selective inhibitors (COX-2) inhibitors
Other Drug Class
By Route of Administration
Injectable
Oral
Topical
Other Routes
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Other Distribution Channels
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Non-steroidal anti-inflammatory drugs (NSAIDs) Segment is Expected to Hold a Major Market Share in the Postoperative Pain Management Market

The non-steroidal anti-inflammatory drugs (NSAIDs) segment is expected to hold a significant market share by drug class. Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to relieve pain, reduce inflammation, and bring down high body temperatures.

The major factors fuelling the segment's growth are the implementation of strategic initiatives by the market players, the growing demand for NSAIDs owing to their advantages over other drugs, and the increasing number of surgical procedures. For instance, in July 2021, Hyloris Pharmaceuticals SA, a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, reported that Maxigesic IV would be available in Germany and Austria. Maxigesic IV is a novel, patented, non-steroidal anti-inflammatory drug that is a unique combination of 1000 mg paracetamol and 300 mg ibuprofen solution for infusion. Hyloris' partner company, AFT Pharmaceuticals, works with distribution partners with a strong local presence to commercialize the product worldwide.

Moreover, as per a June 2021 published study titled "Managing postoperative pain in adult outpatients: a systematic review and meta-analysis comparing codeine with NSAIDs," adult outpatients reported better pain scores, better global assessments, and fewer adverse effects when their postoperative pain was treated with NSAIDs than with codeine. Such studies indicating the efficacy of NSAIDs in postoperative pain management contribute to the segment's growth.

Thus, the segment is expected to witness significant growth over the forecast period due to the abovementioned factors.

Post Operative Pain Management Market Trends

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

The United States is expected to hold a major share of the market in North America. The major factors bolstering the market's growth are the growing number of surgical procedures, surge in awareness regarding postoperative pain management drugs, increasing number of product approvals, and rising focus on palliative care.

For instance, a research study titled "Comparison of Postoperative Pain Management Outcomes in the United States and China," published on PubMed.gov in November 2021, stated that the American Pain Society Patient Outcome Questionnaire-Revised (APS-POQ-R) was completed by 244 patients in the United States and 268 patients in China with similar surgery sites. The Pain Management Index (PMI) was calculated on their first postoperative day. Patients in the United States had a higher score on the APS-POQ "perception of pain management" subscale and a larger proportion of acceptable treatment, as assessed by the PMI. In patients from both nations, patient education and degrees of pain reduction predicted patient satisfaction with pain management. In the United States, higher compliance with pain management recommendations has resulted in higher perceptions among patients. Such statistics are likely to increase the demand for postoperative pain management medications within the country, thereby boosting the market's growth.

In addition, several market players are engaged in implementing strategic initiatives, thereby contributing to the market's growth. For instance, in May 2021, Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform postsurgical pain management and recovery, reported the first-ever clinical data showing non-opioid pain relief lasting two weeks after a single administration.

Moreover, an increasing number of product approvals is also expected to contribute to the market's growth. For instance, in May 2021, Heron Therapeutics, Inc., a commercial-stage biotechnology company focused on developing treatments to address some of the most important unmet patient needs, reported that the United States Food and Drug Administration (FDA) has approved ZYNRELEF (bupivacaine and meloxicam) extended-release solution for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after a bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty.

Thus, owing to the abovementioned factors, the market is expected to witness significant growth over the forecast period.

Post Operative Pain Management Market Growth

Competitive Landscape

The postoperative pain management market is fragmented, with the presence of several global and international market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are Pfizer Inc., AbbVie, GlaxoSmithKline plc, Heron Therapeutics, and AFT Pharmaceuticals.

Recent Developments

In March 2022, Heron Therapeutics, Inc. reported that Health Canada had issued a Notice of Compliance (NOC) to commercialize ZYNRELEF (bupivacaine and meloxicam extended-release solution) for instillation into the surgical wound for postoperative analgesia after a bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty surgical procedures.

In March 2022, Cali Biosciences Co., Ltd., a biopharmaceutical company focused on the research and development of innovative drugs, reported successful results in its Phase IIb study of its perioperative long-acting analgesic product CPL-01.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Number of Surgical Procedures

      2. 4.2.2 Increasing Demand for Non-Opioid Based Anaelgesics

      3. 4.2.3 Increasing Focus Towards Palliative Care

    3. 4.3 Market Restraints

      1. 4.3.1 Concerns Pertaining to the Overuse of Opioids

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value -USD million)

    1. 5.1 By Drug Class

      1. 5.1.1 Opioids

      2. 5.1.2 Non-steroidal anti-inflammatory drugs (NSAIDS)

      3. 5.1.3 Cyclooxygenase-2-selective inhibitors (COX-2) inhibitors

      4. 5.1.4 Other Drug Class

    2. 5.2 By Route of Administration

      1. 5.2.1 Injectable

      2. 5.2.2 Oral

      3. 5.2.3 Topical

      4. 5.2.4 Other Routes

    3. 5.3 By Distribution Channel

      1. 5.3.1 Hospital Pharmacies

      2. 5.3.2 Retail Pharmacies

      3. 5.3.3 Other Distribution Channels

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AbbVie (Allergan)

      2. 6.1.2 Heron Therapeutics

      3. 6.1.3 Cali Biosciences

      4. 6.1.4 Acadia Pharmaceuticals

      5. 6.1.5 Virpax Pharmaceuticals

      6. 6.1.6 GlaxoSmithKline Plc

      7. 6.1.7 Pacira Pharmaceuticals Inc.

      8. 6.1.8 Johnson & Johnson (Janssen Pharmaceuticals)

      9. 6.1.9 AFT Pharmaceuticals

      10. 6.1.10 Alembic Pharmaceuticals

      11. 6.1.11 InvaGen Pharmaceuticals Inc.

      12. 6.1.12 SiteOne Therapeutics

      13. 6.1.13 Pfizer Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Post Operative Pain Management Market market is studied from 2019 - 2027.

The Global Post Operative Pain Management Market is growing at a CAGR of 4.8% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

AbbVie (Allergan), Heron Therapeutics, Pfizer Inc., AFT Pharmaceuticals, GlaxoSmithKline plc are the major companies operating in Global Post Operative Pain Management Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!